Interface Biologics closes $5 Million financing

Printer Print Email Email
Toronto: Interface Biologics, a privately held developer of novel biomedical-polymers for use in implantable medical devices, has secured a $5 million financing round. The existing investors Covington Capital, VG Partners and BDC Capital participated in the round. In connection with the financing, Lily Lam from Covington Capital is joining the Board of Directors and Thomas P. Reeves has been appointed the new President and CEO and is also joining the Board of Directors. "We are fully committed to Interface Biologics and are excited about the continued commercialization opportunities for the Company in the near future. We believe Tom Reeves' broad leadership experience - most recently as President and COO of OccuLogix - will complement our existing scientific and technical expertise as we move into the clinical application and commercialization phase with many of the Company's novel polymer products," said Jeff Courtney, General Partner of VG Partners. Interface Biologics is a biomaterials company based in Toronto, Canada developing proprietary, nano-engineered biomedical-polymers for use in implantable medical devices.

siliconindia